# mRNA / LNP manufacturing equipment The mixers, skids and continuous-flow reactors that bring an mRNA payload and a four-lipid ethanol blend together in microseconds to self-assemble 80–120 nm lipid nanoparticles — the hardware layer behind every commercial mRNA vaccine and the in-vivo delivery system for the next generation of gene therapy. Source: https://en.bioecon.ru/technology/mrna-lnp-manufacturing-equipment/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: EU GMP Annex 1 & ICH Q13 continuous manufacturing | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] mRNA / LNP manufacturing equipment is the set of mixers, skids and continuous-flow reactors that combine an aqueous mRNA stream with an ethanol-dissolved lipid blend so the four components — ionizable lipid, cholesterol, helper phospholipid and PEG-lipid — self-assemble around the mRNA into lipid nanoparticles of 80–120 nm in a few milliseconds. Two mixing geometries dominate the commercial field: impingement-jet mixing (IJM), which collides the two streams head-on inside a confined chamber at high velocity, and microfluidic staggered-herringbone mixing, which interleaves the streams in a lithographic channel. Both run continuously, scale by holding residence time constant, and feed straight into a downstream tangential-flow filtration (TFF) step that removes the ethanol and conditions the buffer before sterile fill-finish. The platform is the hardware layer behind the multi-billion-dose mRNA COVID-19 vaccines and the in-vivo delivery system for a fast-growing pipeline of gene-editing, vaccine and protein-replacement therapies. The key directions of mRNA / LNP manufacturing equipment are: 1. **Benchtop microfluidic screening (NanoAssemblr Ignite/Spark):** milligram-scale staggered-herringbone mixers that let formulators sweep the flow-rate ratio, lipid composition and N/P ratio in overnight design-of-experiments runs before committing to GMP scale. 2. **GMP impingement-jet skids (Knauer IJM NanoScaler/NanoProducer):** the high-velocity collision geometry used to manufacture commercial mRNA vaccines, scaled by Reynolds-number matching from a benchtop NanoScaler to a multi-litre-per-minute production skid. 3. **Production microfluidic platforms (NanoAssemblr Blaze/Gemini, Microfluidizer M7250):** parallelised microfluidic cartridges or high-pressure interaction chambers delivering kilograms of mRNA-LNP per batch under single-use, GMP-clean flow paths. 4. **Continuous-flow reactors (Corning Advanced-Flow Reactor):** structured plate-and-frame continuous reactors (G1–G4) that turn LNP formation into a true continuous process aligned with ICH Q13, rather than a batch-overflowing stirred vessel. ### Sectoral value chain ``` [lipid & mRNA preparation] ──> [continuous mixing (IJM/microfluidic/AFR)] ──> [quench & dilution] │ (downstream TFF + sterile filtration) │ ▼ [distribution & cold chain] <─── [fill-finish] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Lipid & mRNA preparation** | dissolving the four-lipid blend in ethanol and the mRNA in aqueous buffer | **In:** ionizable lipid, cholesterol, helper lipid, PEG-lipid, mRNA bulk. **Out:** two feed streams. | | **Continuous mixing** | IJM, microfluidic or AFR contactor bringing the streams together at a tuned flow-rate ratio | **In:** two feed streams. **Out:** crude mRNA-LNP in ~30–50% ethanol. | | **Quench & dilution** | immediate buffer dilution to stabilise the particle and stop growth | **In:** crude mRNA-LNP. **Out:** diluted LNP dispersion. | | **Downstream TFF** | tangential-flow filtration to remove ethanol and exchange buffer | **In:** diluted dispersion. **Out:** formulated mRNA-LNP (<1% ethanol). | | **Sterile filtration & fill** | 0.22 μm filtration into vials, syringes or bags under GMP Annex 1 | **In:** formulated LNP. **Out:** filled drug product. | | **Cold-chain distribution** | frozen or refrigerated logistics at -70 °C to 2–8 °C to point of use | **In:** filled drug product. **Out:** administered dose. | Cross-cutting technologies of the sector: - **Impingement-jet mixing (Impingement-Jet Mixing):** high-velocity stream collision in a confined chamber, the commercial-scale mixer geometry behind mRNA COVID-19 vaccines. - **Microfluidic LNP formulation (Microfluidic LNP Formulation):** lithographic-channel mixing that controls LNP size (30–270 nm) by tuning flow-rate ratio. - **Tangential-flow filtration (Tangential-Flow Filtration):** the downstream ethanol-removal and buffer-exchange step that every continuous mixer feeds into. --- ## US The United States is the centre of the microfluidic-mixing platform class, and the home of two of its three dominant hardware vendors: Precision NanoSystems (Vancouver, CA, a Cytiva company since 2020) and Microfluidics International (Westwood, MA). Corning (Corning, NY) adds the continuous Advanced-Flow Reactor family, and FDA's emergency-use and full-approval pathways for mRNA vaccines are what pulled the platform from research into multi-billion-dose commercial scale. ### microfluidic mixer platforms, AFR continuous reactors, FDA mRNA pathway - **Precision NanoSystems — NanoAssemblr:** the staggered-herringbone platform (Ignite benchtop, Spark clinical, Blaze and Gemini commercial, Bio-Continuum continuous manufacturing) that set the de-facto LNP-process-development standard. - **Microfluidics International — Microfluidizer:** high-pressure fixed-geometry interaction chambers (LM20 benchtop, M7250 production) producing uniform sub-100 nm LNP across high-shear homogenisation. - **Corning — Advanced-Flow Reactor (AFR):** the G1–G4 plate-and-frame continuous reactor class, qualified for LNP and mRNA continuous manufacturing under ICH Q13. --- ## CN China is the demand-side growth market for mRNA / LNP equipment: a wave of domestic mRNA vaccines (COVID-19, RSV, oncology) and the country's cell and gene therapy pipeline are converting imported-mixer R&D lines into domestic commercial production, while NMPA's reliance on ICH Q13 harmonises the continuous-manufacturing framework. Domestic fill-finish and bioprocessing equipment makers are pivoting toward integrated mRNA-LNP preparation lines, but the upstream microfluidic/impingement mixer hardware at production scale remains substantially imported, so the Chinese regional block is held qualitative. ### domestic fill-finish pivot, ICH Q13 alignment, imported upstream mixers - **Domestic mRNA vaccine drive:** Walvax/Abogen, Stemirna and CSPC mRNA programmes have built commercial-scale LNP capacity around imported NanoAssemblr and Knauer IJM skids, with domestic media, lipid and TFF supply localised around them. - **Fill-finish and bioprocessing equipment makers:** domestic firms with established aseptic-filling and bioreactor lines are extending into mRNA-LNP preparation skids, but the microfluidic and impingement-jet contactor is still primarily imported at production scale. - **NMPA continuous-manufacturing alignment:** NMPA adoption of ICH Q13 frames the regulatory route for continuous LNP manufacturing, paralleling FDA and EMA. --- ## EU Europe anchors the impingement-jet side of the field and the CDMO offer: Knauer (Berlin, DE) builds the IJM skid family that manufactures commercial mRNA vaccines, while Evonik (Essen, DE) operates a lipid and LNP contract-development-and-manufacturing network expanded through the 2024 Wilshire acquisition, and EMA's EU GMP Annex 1 and ICH Q13 guidance define the aseptic and continuous-manufacturing bar. ### impingement-jet skids, lipid/CDMO capacity, GMP Annex 1 - **Knauer — IJM NanoScaler & NanoProducer:** the impingement-jet family scaled by Reynolds-number matching from benchtop NanoScaler to production NanoProducer, developed with partners such as XNApharma for RNA delivery screening. - **Evonik — Wilshire continuous processing & lipids:** Evonik Health Care's LNP CDMO, expanded through the Wilshire acquisition, pairs lipid supply with continuous processing and high-shear expertise. - **EMA GMP Annex 1 & ICH Q13:** the EU aseptic-processing and continuous-manufacturing framework that qualifies LNP formation, downstream TFF and aseptic fill-finish. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Precision NanoSystems** | 🇨🇦 Canada | *NanoAssemblr Ignite/Spark/Blaze/Gemini* | Staggered-herringbone microfluidic mixer (Cytiva company); scales 1 mL to multi-litre continuous Bio-Continuum | Commercial | | **Knauer** | 🇩🇪 Germany | *IJM NanoScaler, NanoProducer* | Impingement-jet collision mixer scaled by Reynolds number; commercial mRNA vaccine manufacturing | Commercial | | **Microfluidics International** | 🇺🇸 USA | *Microfluidizer LM20, M7250* | High-pressure fixed-geometry interaction chamber; sub-100 nm LNP at production scale | Commercial | | **Corning** | 🇺🇸 USA | *Advanced-Flow Reactor G1–G4* | Plate-and-frame continuous reactor qualified for LNP/mRNA under ICH Q13 | Commercial | | **Evonik** | 🇩🇪 Germany | *Wilshire continuous processing, lipid supply* | LNP CDMO pairing lipid manufacturing with continuous/high-shear processing | Commercial | --- ## Tech stack and innovations The stack combines the mixer contactor, the downstream TFF train and continuous-manufacturing control into one closed flow path. 1. **Mixer contactors (Mixer Contactors):** - impingement-jet chambers (Knauer IJM) colliding the two streams at high velocity, scaled by Reynolds-number matching; - staggered-herringbone microfluidic cartridges (Precision NanoSystems NanoAssemblr) controlling LNP size (30–270 nm) by flow-rate ratio; - high-pressure fixed-geometry interaction chambers (Microfluidics Microfluidizer) and plate-and-frame AFR contactors (Corning). 2. **Downstream TFF train (Downstream TFF Train):** - single-use tangential-flow cassettes that remove ethanol from the crude LNP dispersion and exchange the buffer to <1% residual organic; - inline dynamic-light-scattering PAT tracking particle size and polydispersity in real time. 3. **Continuous-manufacturing control (Continuous-Manufacturing Control):** - ICH Q13-aligned process control with flow-rate-ratio and total-flow feedback, enabling true continuous LNP formation rather than batch overflow. --- ## Value chains and production pipelines ### Industrial pipeline of an mRNA-LNP manufacturing skid (ICH Q13 / GMP Annex 1) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Lipid & mRNA feed prep │ ───> │ 2. Continuous mixing │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Downstream TFF │ <─── │ 3. Quench & dilution │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Sterile filtration │ ───> │ 6. Fill-finish & cold chain│ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Lipid and mRNA feed preparation The four-lipid blend (ionizable lipid, cholesterol, helper phospholipid, PEG-lipid) is dissolved in ethanol, and the mRNA bulk — produced by in-vitro transcription and purified — is held in aqueous buffer as two separate feed streams. #### Stage 2: Continuous mixing The two streams meet in the mixer contactor — impingement-jet (Knauer IJM), staggered-herringbone microfluidic (NanoAssemblr), high-pressure interaction chamber (Microfluidizer) or plate-and-frame (Corning AFR) — at a tuned flow-rate ratio (typically ~1:3 organic:aqueous) and controlled total flow, self-assembling 80–120 nm lipid nanoparticles in milliseconds. #### Stage 3: Quench and dilution The crude LNP dispersion, still in ~30–50% ethanol, is immediately diluted with buffer to stabilise particle size, stop growth and bring encapsulation efficiency above 90%. #### Stage 4: Downstream TFF Single-use tangential-flow filtration cassettes remove the ethanol and exchange the buffer down to <1% residual organic, with inline DLS PAT confirming particle size and polydispersity hold. #### Stage 5: Sterile filtration The formulated LNP passes a 0.22 μm sterile filter into the fill-finish suite under EU GMP Annex 1 aseptic conditions, with container-closure integrity verified per batch. #### Stage 6: Fill-finish and cold chain The sterile LNP drug product is filled into vials, syringes or bags, lyophilised or frozen where required, and distributed at -70 °C to 2–8 °C through validated cold chain to the point of administration.